Placental MSC infusion is a brief outpatient procedure; acute effects resolve within 48 hours. Functional improvement in skin mobility and hand range of motion typically emerges over 4–8 weeks. HSCT involves 4–6 weeks of intensive inpatient care during conditioning and recovery, followed by 6–12 months of restricted activity and close monitoring; full functional recovery takes months.
Forty-two completed trials and 7 currently recruiting trials are registered for systemic sclerosis, with diverse cell sources (placental MSC predominating, alongside autologous bone-marrow-derived MSC and HSCT). HSCT trials have shown arrest or reversal of skin fibrosis in approximately 70–80% of treated patients, with sustained benefit at 5-year follow-up in many, though the treatment carries significant morbidity (infection risk, infertility, relapse). MSC trials are smaller and earlier-stage; published data show stabilisation of skin thickening (modified Rodnan skin score stability or improvement) in 50–70% of placental MSC-treated participants over 6–24 months, often accompanied by improved lung function and hand mobility.
האם אני מועמד? → · Scleroderma (Systemic Sclerosis): full overview → · עלות סקלרודרמה (סקלרוזיס מערכתית) → · Cost →
בדוקה רפואית על ידי צוות העריכה של StemCellAtlas עם Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) של קליניקת השותף Stem Plus (סופיה), כנגד הנחיות ISSCR, FDA ו-EMA. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם